Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

19th Congress of the European Hematology Association (EHA 19)

12 - 15 Jun 2014

MiCo, Milan, Italy

Treatment options in adult chronic idiopathic thrombocytopenic purpura: Introduction

Prof Aristoteles Giagounidis - St John’s Hospital, Duisburg, Germany

Treatment options in adult chronic idiopathic thrombocytopenic purpura: Introduction ( Prof Aristoteles Giagounidis - St John’s Hospital, Duisburg, Germany )

Hot topic: B-cell depletion in adult chronic ITP

Dr Francesco Zaja - University of Udine, Udine, Italy

Hot topic: B-cell depletion in adult chronic ITP ( Dr Francesco Zaja - University of Udine, Udine, Italy )

Thrombosis in adult patients with chronic ITP

Dr Howard Liebman - University of Southern California, Los Angeles, USA

Thrombosis in adult patients with chronic ITP ( Dr Howard Liebman - University of Southern California, Los Angeles, USA )

Effects of one TPO-R agonist after discontinuing another?

Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany

Effects of one TPO-R agonist after discontinuing another? ( Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany )

Prolonged response to TPO-R agonists

Dr James Bussel - Cornell University, Ithaca, USA

Prolonged response to TPO-R agonists ( Dr James Bussel - Cornell University, Ithaca, USA )

How do TPO-R agonists impact the daily lives of chronic ITP patients? Lessons from long-term studies

Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany

How do TPO-R agonists impact the daily lives of chronic ITP patients? Lessons from long-term studies ( Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany )

Treatment options in adult chronic idiopathic thrombocytopenic purpura: Panel discussion

Prof Aristoteles Giagounidis; Dr Francesco Zaja; Dr James Bussel; Dr Howard Liebman

Treatment options in adult chronic idiopathic thrombocytopenic purpura: Panel discussion ( Prof Aristoteles Giagounidis; Dr Francesco Zaja; Dr James Bussel; Dr Howard Liebman )

Tackling inequality in access to cancer care and information

Prof Mark Lawler - Queen's University Belfast, Belfast, UK

Tackling inequality in access to cancer care and information ( Prof Mark Lawler - Queen's University Belfast, Belfast, UK )

Retinoic acid in acute promyelocytic leukaemia as alternative to chemotherapy

Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy

Retinoic acid in acute promyelocytic leukaemia as alternative to chemotherapy ( Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy )

Relationship between metabolism and cancer growth in acute promyelocytic leukaemia

Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy

Relationship between metabolism and cancer growth in acute promyelocytic leukaemia ( Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy )

Gdf -11 a new target to improve anaemia in thalassemia

Prof Olivier Hermine - Université Paris Descartes, Paris, France

Gdf -11 a new target to improve anaemia in thalassemia ( Prof Olivier Hermine - Université Paris Descartes, Paris, France )

Advances in multiple myeloma: Expert discussion

Prof Sonja Zweegman and Prof Matti Aapro

Advances in multiple myeloma: Expert discussion ( Prof Sonja Zweegman and Prof Matti Aapro )

Biomarkers in CLL prognosis

Prof Robin Foà - Sapienza University of Rome, Rome, Italy

Biomarkers in CLL prognosis ( Prof Robin Foà - Sapienza University of Rome, Rome, Italy )

Philadelphia chromosome and the role it plays in chronic myeloid leukaemia

Prof Christine Harrison - Newcastle University, Newcastle, UK

Philadelphia chromosome and the role it plays in chronic myeloid leukaemia ( Prof Christine Harrison - Newcastle University, Newcastle, UK )

Eltrombopag helped reduce bleeding in children with immune thrombocytopenic purpura

Dr John Grainger - Royal Manchester Children's Hospital, Manchester, UK

Eltrombopag helped reduce bleeding in children with immune thrombocytopenic purpura ( Dr John Grainger - Royal Manchester Children's Hospital, Manchester, UK )

Pivotal ruxolitinib data shows promise for patients with PV

Prof Alessandro Vannucchi - University of Florence, Florence, Italy

Pivotal ruxolitinib data shows promise for patients with PV ( Prof Alessandro Vannucchi - University of Florence, Florence, Italy )

Multiple myeloma in the elderly: Expert discussion

Prof Philippe Moreau and Prof Marivi Mateos

Multiple myeloma in the elderly: Expert discussion ( Prof Philippe Moreau and Prof Marivi Mateos )

Personalised medicine in Europe needs to be accessible to all

Prof Mark Lawler - Queen's University Belfast, Belfast, UK

Personalised medicine in Europe needs to be accessible to all ( Prof Mark Lawler - Queen's University Belfast, Belfast, UK )

Treatment of acute lymphoblastic leukaemia by activation of patient's immune cells by a bispecific antibody

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

Treatment of acute lymphoblastic leukaemia by activation of patient's immune cells by a bispecific antibody ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )

Novel targeting in acute myeloid leukaemia

Prof Giovanni Martinelli - University of Bologna, Bologna, Italy

Novel targeting in acute myeloid leukaemia ( Prof Giovanni Martinelli - University of Bologna, Bologna, Italy )

Better understandings of gene mutations aid diagnostic tools in CLL

Dr Elías Campo - University of Barcelona, Barcelona, Spain

Better understandings of gene mutations aid diagnostic tools in CLL ( Dr Elías Campo - University of Barcelona, Barcelona, Spain )

Eltrombopag helped reduce bleeding in children with immune thrombocytopenic purpura

Dr John Grainger - Royal Manchester Children's Hospital, Manchester, UK

Eltrombopag helped reduce bleeding in children with immune thrombocytopenic purpura ( Dr John Grainger - Royal Manchester Children's Hospital, Manchester, UK )

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )

Lenalidomide versus thalidomide in myeloma

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

Lenalidomide versus thalidomide in myeloma ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Comment: Advances in haematological cancer presented at EHA 2014

Prof Pieter Sonneveld - University Hospital Rotterdam, Netherlands

Comment: Advances in haematological cancer presented at EHA 2014 ( Prof Pieter Sonneveld - University Hospital Rotterdam, Netherlands )

Advances in mantle cell lymphoma: Expert discussion

Prof Simon Rule and Prof Franco Cavalli

Advances in mantle cell lymphoma: Expert discussion ( Prof Simon Rule and Prof Franco Cavalli )

Advances in chronic lymphocytic leukaemia: Expert panel discussion

Prof Peter Hillmen; Prof John Gribben; Prof Stephen Mulligan

Advances in chronic lymphocytic leukaemia: Expert panel discussion ( Prof Peter Hillmen; Prof John Gribben; Prof Stephen Mulligan )

Genetically modified T cells fight haematological cancer

Dr Roman Galetto - Cellectis Therapeutics, Paris, France

Genetically modified T cells fight haematological cancer ( Dr Roman Galetto - Cellectis Therapeutics, Paris, France )

Pivotal ruxolitinib data shows promise for patients with PV

Prof Alessandro Vannucchi - University of Florence, Florence, Italy

Pivotal ruxolitinib data shows promise for patients with PV ( Prof Alessandro Vannucchi - University of Florence, Florence, Italy )

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )

Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety?

Dr Zafer Başlar - Istanbul University, Istanbul, Turkey

Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety? ( Dr Zafer Başlar - Istanbul University, Istanbul, Turkey )

Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows

Prof Peter Hillmen - St James’ University Hospital, Leeds, UK

Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows ( Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )

More from ecancer